DelveInsight’s ‘Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Neuroblastoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Neuroblastoma from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Neuroblastoma - Disease Understanding and Treatment Algorithm
The DelveInsight Neuroblastoma market report gives the thorough understanding of Neuroblastoma by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroblastoma in the US, Europe, and Japan.
The Neuroblastoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total incident patient population and incident cases by risk groups (Low risk, intermediate risk and high risk)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, total incident cases of Neuroblastoma in 7 major markets is found to be about 1530 in 2016.
Neuroblastoma Drug Chapters
This segment of Neuroblastoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Given the nature of the cancer and multimodal treatment options available for Neuroblstoma, various systemic therapies were administered. The therapies which are used to treat Neuroblastoma are Chemotherapies (Chemotherapy agents from: Cyclophosphamide, etoposide, doxorubicin, carboplatin, topotecan, cisplatin, vincristine, melphalan, busulfan, etc), Retinoid therapy (Isotretinoin) and Immunotherapies (Qarziba and Unituxin).
Detailed chapter for upcoming therapies Naxitamab (Y-mAbs Therapeutics Inc.), Omburtamab (Y-mAbs Therapeutics Inc.), Bevacizumab, Irinotecan and Temozolomide (Genentech, Inc), CPP-1X (Cancer Prevention Pharmaceuticals), MNX-100 (MetronomX) etc., have been covered in the report.
Neuroblastoma Market Outlook
The Neuroblastoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Neuroblastoma in 7MM was found to be USD 733.58 million in 2016, and is expected to increase at from 2016-2027.
Neuroblastoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Neuroblastoma Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Neuroblastoma Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Neuroblastoma Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Neuroblastoma market
• Organize sales and marketing efforts by identifying the best opportunities for Neuroblastoma market
• To understand the future market competition in the Neuroblastoma market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook